Hepatitis c blood study halted early: what it means
NCT ID NCT06564051
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see how often people with chronic hepatitis C have a blood condition called monoclonal B-cell lymphocytosis (MBL), and whether treating hepatitis C affects MBL. Researchers planned to enroll 29 participants and compare blood samples before and after hepatitis C treatment. However, the study was terminated early, so the findings are incomplete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What could go wrong
- The study was terminated early with only 29 participants, so results are limited and may not be reliable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?
- Blood test and AI could spot liver cancer early, saving lives
- Massive study aims to map hepatitis c elimination in pakistan
- Can a blood pressure drug reverse liver damage in hepatitis c?
- New hepatitis c drug combo shows promise in early trial
- New study tests faster hepatitis c detection for drug users